Aerie Pharmaceuticals, Inc., has filed a Form S-1 registration statement with the U.S. Securities and Exchange Commission outlining its plans to raise nearly $58 million through an initial public offering (IPO). The Bedminster, New Jersey-based developer of glaucoma drugs reportedly plans to use the funds to build a sales force, move one glaucoma drug candidate known as AR-13324 through a late-stage clinical trial, and another, PG324, through a Phase 2b study. RBC Capital Markets and Stifel Nicolaus & Co. will serve as joint book-running managers for the offering, and Lazard Capital Markets and Canaccord Genuity will serve as co-managers.

According to a news source, if the company’s clinical trials succeed, it plans to commercialize a group of drugs to treat glaucoma—a condition in which fluid builds inside the eye, putting pressure on and ultimately damaging the optic nerve.See Aerie Pharmaceuticals, Inc. News Release, September 17, 2013; xconomy.com, September 18, 2013.